APLSUSD

Apellis Pharmaceuticals INC

+$2.3B

Net Activity

Institutions Holding

326

Popularity Rank

#1827

Avg Weight

0.25%

Total Value

$5.6B

Ownership Trend

326 institutions currently hold APLSUSD, with 208 net buyers and 154 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

154

Net Buying Institutions

208

Key Holders

View all 326 holding institutions

Quarterly Activity

Recent Activity

+$15.9B

Total Buy Value

$1.7B

Total Sell Value

New buy115
Trim75
Add93
Sold out79

208

Net Buyers

154

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding APELLIS PHARMACEUTICALS INC (APLSUSD)?
Major stakeholders currently include BlackRock, Inc. ($544.6M), Avoro Capital Advisors LLC ($491.7M), Morgan Stanley ($404.0M). Based on the latest 13F filings, there are a total of 326 tracked investment funds and institutions maintaining positions in APLSUSD.
What is the overall institutional sentiment toward APLSUSD recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $2.3B, driven by 208 managers accumulating shares while 154 reduced their exposure.
Which institutions have been selling or reducing their APLSUSD positions?
In the latest period, 75 funds trimmed their holdings, and 79 managers completely exited their positions. The aggregate reported sell value was $1.7B.
Are there any notable investors adding APLSUSD to their portfolios?
Yes, buying activity remains notable. 115 institutions opened new positions in {ticker}, and 93 existing holders added to their shares. The total reported buy value for the quarter amounted to $15.9B.

Related Stocks